News
Campaign calls for menopause support in cancer care
Campaigners are urging menopause support to be included in cancer treatment plans after a survey found 90 per cent of patients were given no guidance.
The survey of 1,200 people revealed most had no support for managing menopausal changes triggered by treatment.
The research was carried out by Menopause and Cancer, whose founder and CEO Dani Binnington said the results were “not a surprise.”
Many cancer treatments, particularly those for breast cancer, can cause early or sudden menopause by affecting hormones or ovarian function.
Binnington said there is currently no direct pathway for support in care plans.
She said: “We call for improved training for healthcare professionals, better access to therapies and specialist care so people can manage menopause safely and effectively.”
Binnington, from Thames Ditton, Surrey, was diagnosed with breast cancer at 33.
Her treatment brought on early menopause at 39, leading her to set up the charity to support patients and run workshops for healthcare professionals.
Rachel Bowman, director of Menopause and Cancer, from Brighton, East Sussex, was first diagnosed with breast cancer at 46 while on hormone replacement therapy (HRT) for perimenopause symptoms.
She received a management plan only after being diagnosed again in 2023.
She said: “Support teams who have this specific experience is very patchy.”
Dr Carys Sonnenberg, a GP and menopause specialist from Surrey, said oncology had historically focused on treating and surviving cancer, with “less attention to long-term quality of life issues including menopause.”
“Oncology, gynaecology, and primary care may not always coordinate well, so patients can fall between the cracks,” she added.
Dr Sonnenberg said menopause care should be integrated into treatment plans from the outset.
Menopause and Cancer also runs workshops for healthcare professionals to equip them with the knowledge to support patients experiencing treatment-induced menopause, addressing the lack of joined-up care pathways.
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now








